



# BENIGN PROSTATIC HYPERPLASIA

RMA ID Number	Reference List for RMA051-3 as at December 2024
---------------	---

76207	Abrams P (1994). New words for old: lower urinary tract symptoms for "prostatism". <i>BMJ</i> , 308: 929-30.
46911	Agency for Toxic Substances and Disease Registry (2007). Toxicological Profile for Lead. US Department of Health and Human Services, Public Health Service.
40509	Ambrosini GL, de Klerk NH, Mackerras D, et al (2007). Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. <i>BJU Int</i> , 101(7): 853-60.
15397	Araki H, Watanabe H, Mishina T, et al (1983). High-risk group for benign prostatic hypertrophy. <i>Prostate</i> , 4(3): 253-64.
3273	Armenian HK, Lilienfeld AM, Diamond EL, et al (1975). Epidemiologic characteristics of patients with prostatic neoplasms. <i>Am J Epidemiol</i> , 102(1): 47-54.
76174	Aune D, Rosenblatt D, Chan D, et al (2015). Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. <i>Am J Clin Nutr</i> , 101(1): 87-117.
119267	Australian Medicines Handbook (2024). Beta-blockers. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/cardiovascular-drugs/antihypertensives/beta-blockers">https://amhonline.amh.net.au/chapters/cardiovascular-drugs/antihypertensives/beta-blockers</a>
119269	Australian Medicines Handbook (2024). Dyslipidaemia. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/cardiovascular-drugs/drugs-dyslipidaemia/dyslipidaemia">https://amhonline.amh.net.au/chapters/cardiovascular-drugs/drugs-dyslipidaemia/dyslipidaemia</a>
119266	Australian Medicines Handbook (2024). Epilepsy. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/neurological-drugs/antiepileptics/epilepsy">https://amhonline.amh.net.au/chapters/neurological-drugs/antiepileptics/epilepsy</a>
119270	Australian Medicines Handbook (2024). General principles: antineoplastics. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/general-principles-antineoplastics?menu=vertical">https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/general-principles-antineoplastics?menu=vertical</a>
119265	Australian Medicines Handbook (2024). Major depression. Retrieved 4 July 2024, from <a href="https://amhonline.amh.net.au/chapters/psychotropic-drugs/antidepressants/major-depression">https://amhonline.amh.net.au/chapters/psychotropic-drugs/antidepressants/major-depression</a>
119272	Australian Medicines Handbook (2024). Non-steroidal anti-inflammatory drugs (NSAIDs). Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/rheumatological-drugs/drugs-other-musculoskeletal-conditions/nsaids">https://amhonline.amh.net.au/chapters/rheumatological-drugs/drugs-other-musculoskeletal-conditions/nsaids</a>
119273	Australian Medicines Handbook (2024). Opioid analgesics. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/analgesics/drugs-pain-relief/opioid-analgesics">https://amhonline.amh.net.au/chapters/analgesics/drugs-pain-relief/opioid-analgesics</a>

118633	Australian Medicines Handbook (2024). Testosterone (men). Retrieved 3 June 2024, from <a href="https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-other-endocrine-disorders/androgens/testosterone">https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-other-endocrine-disorders/androgens/testosterone</a>
119274	Australian Medicines Handbook (2024). Type 2 diabetes. Retrieved 31 January 2024, from <a href="https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-diabetes/type-2-diabetes?menu=vertical">https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-diabetes/type-2-diabetes?menu=vertical</a>
119275	Baas W, Kohler TS (2016). Testosterone replacement therapy and BPH/LUTS. What is the evidence? <i>Curr Urol Rep</i> , 17(6): 46.
76213	Barnard R, Aronson W (2009). Benign prostatic hyperplasia: does lifestyle play a role? <i>Phys Sportsmed</i> , 37(4): 141-6.
46855	Barry MJ (2004). Benign prostatic hyperplasia. <i>ACP Medicine</i> , Chapter 13: 1-9. WebMd Inc.
76211	Bechis SK, Otsetov AG, Ge R, et al (2015). Age and obesity promote methylation and suppression of 5alpha-reductase 2: implications for personalized therapy of benign prostatic hyperplasia. <i>J Urol</i> , 194(4): 1031-7.
44917	Berger AP, Bartsch G, Deibl M, et al (2006). Atherosclerosis as a risk factor for benign prostatic hyperplasia. <i>BJU Int</i> , 98(5): 1038-42.
45019	Berger AP, Deibl M, Halpern EJ, et al (2005). Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. <i>Diabetologia</i> , 48: 784-9.
45224	Berger RE (2005). Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. <i>J Urol</i> , 174(2): 589.
76173	Bernichtein S, Pigat N, Capiod T, et al (2015). High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions. <i>PLoS One</i> , 10(5): e0125423.
119279	Besiroglu H, Kadihasanoglu M (2023). Is there a link between non-alcoholic fatty liver disease and benign prostate hyperplasia/lower urinary tract symptoms: a systematic review and a meta-analysis. <i>Metab Syndr Relat Disord</i> , 21(7): 370-7.
46863	Bloomgarden ZT (2006). Aspects of type 2 diabetes and related insulin-resistant states. <i>Diabetes Care</i> , 29(3): 732-40.
45078	Boon TA, van Venrooij GE, Eckhardt MD (2001). Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. <i>Curr Urol Rep</i> , 2(4): 297-301.
11200	Bosch JL, Hop WJ, Schroder FH (1995). Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. <i>Urology</i> , 46(Suppl 3A): 34-40.
11428	Bosch R, LH (1991). Pathogenesis of benign prostatic hyperplasia. <i>European Urology</i> , 20(suppl 2): 27-30.
7012	Bourke JB, Griffin JP (1968). Diabetes Mellitus in patients with benign prostatic hyperplasia. <i>BMJ</i> , 4: 492-3.
45194	Boyle P, Liu G, Jacobson S, et al (2001). Epidemiology and natural history. <i>Benign Prostatic Hyperplasia: 19-68</i> . Health Publication Ltd, Plymbridge Distributors, Plymouth UK.
119283	Bradley CS, Erickson BA, Messersmith EE, et al (2017). Evidence of the impact of diet, fluid intake, caffeine alcohol and tobacco on lower urinary tract symptoms: a systematic review. <i>J Urol</i> , 198(5): 1010-20.
45031	Bravi F, Bosetti C, Dal Maso L, et al (2006). Food groups and risk of benign prostatic hyperplasia. <i>Urology</i> , 67(1): 73-9.
76153	Bravi F, Bosetti C, Dal Maso L, et al (2006). Food groups and risk of benign prostatic hyperplasia. <i>Urology</i> , 67(1): 73-9.
45023	Bravi F, Bosetti C, Dal Maso L, et al (2006). Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. <i>Urology</i> , 67(6): 1205-11.

76212	Breyer BN, Huang WY, Rabkin CS, et al (2015). Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>BJU Int</i> , 117(1): 145-54.
45082	Burke JP, Jacobson DJ, McGree ME, et al (2006). Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. <i>Urology</i> , 67(1): 22-5.
45027	Burke JP, Rhodes T, Jacobson DJ, et al (2006). Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. <i>Am J Epidemiol</i> , 164(1): 41-6.
119284	Cakir SS, Ozcan L, Polat EC, et al (2020). Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. <i>Aging Male</i> , 23(5): 538-43.
44913	Campbell B (2005). High rate of prostate symptoms among Ariaal men from Northern Kenya. <i>Prostate</i> , 62: 83-90.
77005	Cetinkaya M, Cetinkaya H, Ulusoy E, et al (1998). Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia. <i>Prostate</i> , 36(2): 80-4.
76286	Chen I, Tsal Y, Tong Y (2012). Correlations among cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia. <i>Urology</i> , 79: 409-14.
119285	Chen Y, Yu W, Zhou L, et al (2016). Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China. <i>BMJ Open</i> , 6(8): e010863.
76192	Chiu Y, Kao S, Lin H, et al (2015). Benign prostatic enlargement is not associated with diabetes: a population-based study. <i>Andrology</i> , 3(5): 933-6.
45360	Chokkalingam AP, Pollak M, Fillmore CM, et al (2001). Insulin-like growth factors and prostate cancer: a population-based case-control study on China. <i>Cancer Epidemiol Biomarkers Prev</i> , 10(5): 421-7.
119286	Choo MS, Han JH, Shin TY, et al (2015). Alcohol, smoking, physical activity, protein, and lower urinary tract symptoms: prospective longitudinal cohort. <i>Int Neurourol J</i> , 19(3): 197-206.
119287	Chung GE, Yim JY, Kim D, et al (2020). Nonalcoholic fatty liver disease is associated with benign prostate hyperplasia. <i>J Korean Med Sci</i> , 35(22): e164.
76206	Chung JH, Yu JH, Sung LH, et al (2012). Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue. <i>Korean J Urol</i> , 53(2): 109-13. [Abstract]
76151	Chung SD, Lin HC (2011). Increased risk of benign prostatic enlargement among patients with liver cirrhosis: a nationwide population-based study. <i>J Androl</i> , 32(2): 159-64.
7013	Chyou PH, Nomura AM, Stemmermann GN, et al (1993). A prospective study of alcohol, diet and other lifestyle factors in relation to obstructive uropathy. <i>Prostate</i> , 22(3): 253-64.
15637	Colao A, Marzullo P, Ferone D, et al (1998). Prostatic hyperplasia: an unknown feature of acromegaly. <i>J Clin Endocrinol Metab</i> , 83(3): 775-9.
45076	Collins MM, Meigs JB, Barry MJ, et al (2002). Prevalence and correlates of prostatitis in the health professionals follow-up. study cohort. <i>J Urol</i> , 167(3): 1363-6.
76285	Corona G, Monami M, Rastrelli G, et al (2011). Type 2 diabetes mellitus and testosterone: a meta-analysis study. <i>Int J Androl</i> , 34(6 Pt 1): 528-40.
76996	Corona G, Vignozzi L, Rastrelli G, et al (2014). Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. <i>Int J Endocrinol</i> , 2014: 329456.

45148	Corradi G, Bucsek M, Panovics J, et al (1996). Detection of Chlamydia trachomatis in the prostate by in-situ hybridization and by transmission electron microscopy. <i>Int J Androl</i> , 19(2): 109-12.
45021	Costabile RA, Steers WD (2006). How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? <i>J Sex Med</i> , 3: 676-81.
45168	Crispo A, Talamini R, Gallus S, et al (2004). Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. <i>Urology</i> , 64(4): 717-22.
76154	Cunningham G, Kadmon D (2015). Epidemiology and pathogenesis of benign prostatic hyperplasia. Retrieved 19 October 2015, from <a href="http://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benign-prostatic-hyperplasia?source=see_link">http://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benign-prostatic-hyperplasia?source=see_link</a>
76140	Cunningham G, Kadmon D (2015). Patient information: benign prostatic hyperplasia (BPH) (beyond the basics). Retrieved 16 October 2015, from <a href="http://www.uptodate.com.au/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics">http://www.uptodate.com.au/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics</a>
119291	Daher M, Saqer T, Jabr M, et al (2023). Benign prostatic hyperplasia and metabolic syndrome; prevalence and association: a cross-sectional study in Syria. <i>BMC Urol</i> , 23(1): 187.
44908	Dahle SE, Chokkalingam AP, Gao YT, et al (2002). Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. <i>J Urol</i> , 168(2): 599-604.
44915	Dal Maso L, Zucchetto A, Tavani A, et al (2006). Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. <i>Int J Cancer</i> , 118(10): 2632-5.
45356	Daniell HW (1993). Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. <i>J Urol</i> , 149(2): 315-7.
16336	Daniell HW (1993). More stage A prostatic cancers, less surgery for benign hypertrophy in smokers. <i>J Urol</i> , 149(1): 68-72.
119292	Daniels JP, Mirocha J, Adjei M, et al (2024). Serum testosterone and dihydrotestosterone and incidence and progression of lower urinary tract symptoms: results from the REDUCE study. <i>J Urol</i> , 211(1): 101-10.
11487	de Kretser D (1994). Prostatic disease - endocrine factors. <i>Pros Trends</i> , (2): 1-4.
76227	De Nunzio C, Albisinni S, Gacci M, et al (2013). The role of inflammation in the progression of benign prostatic hyperplasia. <i>Curr Bladder Dysfunct Rep</i> , 8(2): 142-9.
11441	de Voogt HJ (1991). Biology of the prostate. <i>Prog Clin Biol Res</i> , 370: 207-12.
45165	Eaton CL (2003). Aetiology and pathogenesis of benign prostatic hyperplasia. <i>Curr Opin Urol</i> , 13(1): 7-10.
76283	Egan K, Burnett A, McVary K (2015). The co-occurring syndrome-coexisting erectile dysfunction and benign prostatic hyperplasia and their clinical correlates in aging men: results from the National Health and Nutrition Examination Survey. <i>Urology</i> , 86(3): 570-80.
45385	Enger SM, Van Den Eeden SK, Sternfeld B, et al (2006). California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. <i>BMC Public Health</i> , 6: 172.
46493	Engstrom G, Henningsohn L, Steineck G, et al (2005). Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. <i>BJU Int</i> , 95(6): 810-5.
76205	Espinosa G (2013). Nutrition and benign prostatic hyperplasia. <i>Curr Opin Urol</i> , 23(1): 38-41.
119293	Feiertag N, Tawfik MM, Loloi J, et al (2023). Should men eat more plants? A systematic review of the literature on the effect of plant-forward diets on men's health. <i>Urology</i> , 176: 7-15.

119296	Feng T, Howard LE, Vidal AC, et al (2017). Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. <i>Int J Urol</i> , 24(2): 151-6.
76280	Fowke JH, Phillips S, Koyama T, et al (2013). Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. <i>BJU Int</i> , 111(1): 122-8.
44918	Fritschi L, Glass DC, Tabrizi JS, et al (2007). Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia. <i>Occup Environ Med</i> , 64(1): 60-5.
46308	Fritschi L, Tabrizi J, Leavy J, et al (2007). Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. <i>Public Health</i> , 121(10): 781-9.
76392	Gacci M, Corona G, Vignozzi L, et al (2015). Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. <i>BJU Int</i> , 115(1): 24-31.
119298	Galeone C, Pelucchi C, Talamini R, et al (2007). Onion and garlic intake and the odds of benign prostatic hyperplasia. <i>Urology</i> , 70(4): 672-6.
15402	Gann PH, Hennekens CH, Longcope C, et al (1995). A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. <i>Prostate</i> , 26(1): 40-9.
15547	Gao SJ, Moore PS (1996). Molecular approaches to the identification of unculturable infectious agents. <i>Emerg Infect Dis</i> , 2(3): 159-67.
11491	Gardiner RA, Johnson WF, Marshall VR (1995). Second international consultation on BPH. <i>Prospectives</i> , 5: 1-2.
44909	Gass R (2002). Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. <i>BJU Int</i> , 90(7): 649-54.
119301	GBD 2019 Benign Prostatic Hyperplasia Collaborators (2022). The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Healthy Longev</i> , 3(11): e754-76.
11258	Geldof AA, Engel C, Rao BR (1992). Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. <i>Urol Res</i> , 20(2): 139-44.
11257	Geller J (1991). Benign prostatic hyperplasia: pathogenesis and medical therapy. <i>J Am Geriatr Soc</i> , 39(12): 1208-16.
16602	Geller J (1998). [Comment] Comment on prostatic hyperplasia in patients with acromegaly. <i>J Clin Endocrinol Metab</i> , 83(7): 2606; authors' reply: 2606-7.
11196	Giovannucci E, Rimm EB, Chute CG, et al (1994). Obesity and benign prostatic hyperplasia. <i>Am J Epidemiol</i> , 140(11): 989-1002.
44921	Girman CJ (1998). Population-based studies of the epidemiology of benign prostatic hyperplasia. <i>Br J Urol</i> , 82(Suppl 1): 34-43.
11190	Gleason PE, Jones JA, Regan JS, et al (1993). Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia. <i>J Urol</i> , 149(6): 1586-92.
7014	Glynn RJ, Champion EW, Bouchard GR, et al (1985). The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. <i>Am J Epidemiol</i> , 121(1): 78-90.
7015	Gordon GG, Altman K, Southren AL, et al (1976). Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. <i>N Engl J Med</i> , 295(15): 793-7.
15523	Gray A, Feldman HA, McKinlay JB, et al (1991). Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. <i>J Clin Endocrinol Metab</i> , 73(5): 1016-25.

3284	Greenwald P, Kirmss V, Polan AK, et al (1974). Cancer of the prostate among men with benign prostatic hyperplasia. <i>J Natl Cancer Inst</i> , 53(2): 335-40.
74374	Greim H, Snyder R (2008). Introduction to the discipline of toxicology. <i>Toxicology and Risk Assessment: A comprehensive introduction</i> , Chapter 1. John Wiley & Sons.
11490	Griffiths K, Davies P, Peeling WB (1995). Endocrine factors in prostatic disease (part 2). <i>Prospectives: Contemporary Issues in Managing Prostatic Disease</i> , 1(2): 1-6.
11488	Griffiths K, Davies P, Peeling WB (1995). Endocrine factors in prostatic disease (part 1). <i>Prospectives: Contemporary Issues in Managing Prostatic Disease</i> , 1(1): 1-5.
15549	Griffiths K, Eaton CL (1994). The pathogenesis of BPH: role of hormones. <i>Prog Clin Biol Res</i> , 386: 33-41.
11429	Griffiths K, Eaton CL, Harper ME, et al (1991). Steroid hormones and the pathogenesis of benign prostatic hyperplasia. <i>Eur Urol</i> , 20(Suppl 1): 68-77.
15398	Gu F (1997). Changes in the prevalence of benign prostatic hyperplasia in China. <i>Chin Med J (Engl)</i> , 110(3): 163-6.
11236	Guess HA (1992). Benign prostatic hyperplasia: antecedents and natural history. <i>Epidemiol Rev</i> , 14: 131-53.
28919	Guess HA (2001). Benign prostatic hyperplasia and prostate cancer. <i>Epidemiol Rev</i> , 23(1): 152-8.
72440	Guidotti TL (2014). Health Risks and Occupation as a Firefighter. Medical Advisory Services, Department of Veterans' Affairs, Commonwealth of Australia.
45030	Gupta A, Gupta S, Pavuk M, et al (2006). Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. <i>Urology</i> , 68(6): 1198-205.
45026	Gupta A, Ketchum N, Roehrborn CG, et al (2006). Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force Veterans. <i>Environ Health Perspect</i> , 114(11): 1649-54.
45206	Gupta A, Schechter A, Aragaki CC, et al (2006). Dioxin exposure and benign prostatic hyperplasia. <i>J Occup Environ Med</i> , 48: 708-14.
119347	Haghpanah A, Masjedi F, Salehipour M, et al (2022). Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. <i>Prostate Cancer Prostatic Dis</i> , 25(1): 27-38.
45081	Haidinger G, Madersbacher S, Waldhoer T, et al (1999). The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. <i>Eur J Epidemiol</i> , 15(8): 717-22.
45080	Hammarsten J, Hogstedt B (1999). Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. <i>Blood Pressure</i> , 8(1): 29-36.
45083	Hammarsten J, Hogstedt B (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. <i>Eur Urol</i> , 39(2): 151-8.
119349	Han IH, Kim JH, Ryu JS (2023). Inflammatory response to <i>Trichomonas vaginalis</i> in the pathogenesis of prostatitis and benign prostatic hyperplasia. <i>Parasites Hosts Dis</i> , 61(1): 2-14.
45334	Hart LE (1999). Physical activity and benign prostatic hyperplasia. <i>Clin J Sport Med</i> , 9(2): 106.
46858	Hassler E, Krakau I, Haggarth L, et al (2001). Questioning questions about symptoms of benign prostatic hyperplasia. <i>Fam Pract</i> , 18(3): 328-32.
76282	He Q, Wang H, Yue Z (2014). Waist circumference and risk of lower urinary tract symptoms: a meta-analysis. <i>Aging Male</i> , 17(4): 223-9.

46869	Heber D (2002). Prostate enlargement: the canary in the coal mine? <i>Am J Clin Nutr</i> , 75(4): 605-6.
15493	Hennenfert B (1997). Prostatitis and benign prostatic hyperplasia: emerging infectious diseases? <i>Emerg Infect Dis</i> , 3(1): 77-8.
45198	Hochreiter WW, Nadler RB, Koch AE, et al (2000). Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. <i>Urology</i> , 56: 1025-9.
45028	Hong J, Kwon S, Woon H, et al (2006). Risk factors for benign prostatic hyperplasia in South Korean men. <i>Urol Int</i> , 76(1): 11-9.
76998	Howe O, O'Malley K, Lavin M, et al (2005). Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia. <i>Rad Res</i> , 164(5): 627-34.
46188	IARC Working Group (2006). Inorganic and organic lead compounds. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 87. World Health Organization.
119351	Iqbal J, Al-Rashed J, Kehinde EO (2016). Detection of <i>Trichomonas vaginalis</i> in prostate tissue and serostatus in patients with asymptomatic benign prostatic hyperplasia. <i>BMC Infect Dis</i> , 16(1): 506.
45196	Irani J, Goujon JM (2000). [Comment] Asymptomatic inflammation and/or infection in benign prostatic inflammation. <i>BJU Int</i> , 85(9): 1155-6.
11430	Isaacs JT (1994). Etiology of benign prostatic hyperplasia. <i>Eur Urol</i> , 25(Suppl 1): 6-9.
11431	Isaacs JT, Coffey DS (1989). Etiology and disease process of benign prostatic hyperplasia. <i>Prostate Suppl</i> , 2: 33-50.
119353	Ivanov A, Antonov P, Hristova-Atanasova E, et al (2023). Changes in lower urinary tract symptoms in benign prostatic hyperplasia patients affected by Covid-19. <i>Urol Int</i> , 107(4): 358-62.
46494	Jarvis TR, Chughtai B, Kaplan SA (2015). Testosterone and benign prostatic hyperplasia. <i>Asian J Androl</i> , 17(2): 212-6.
46862	Joseph MA, Harlow SD, Wei JT, et al (2003). Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. <i>Am J Epidemiol</i> , 157(10): 906-14.
44910	Joseph MA, Wei JT, Harlow SD, et al (2002). Relationship of serum sex-steroid hormones and prostate volume in African American men. <i>Prostate</i> , 53(4): 322-9.
11492	Kadmon D, Thompson TC (1995). Mechanisms of developing androgen independence in carcinoma of the prostate. <i>Prospectives: Contemporary Issues in Managing Prostatic Disease</i> , 5(5): 1, 7-8.
119354	Kahokehr A, Vather R, Nixon A, et al (2013). Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. <i>BJU Int</i> , 111(2): 304-11.
44912	Kang D, Andriole GL, Van De Vooren RC, et al (2004). Risk behaviours and benign prostatic hyperplasia. <i>BJU Int</i> , 93(9): 1241-5.
45202	Kaplan SA (2005). The relation of lower urinary tract symptoms with lifestyle factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. <i>J Urol</i> , 173(6): 2058.
66022	Kasper JS, Giovannucci E (2006). A meta-analysis of diabetes mellitus and the risk of prostate cancer. <i>Cancer Epidemiol Biomarkers Prev</i> , 15(11): 2056-62.
45020	Kasturi S, Russell S, McVary KT (2006). Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Curr Urol Rep</i> , 7(4): 288-92.
32506	Kaufman JM (2003). The effect of androgen supplementation therapy on the prostate. <i>Aging Male</i> , 6(3): 166-74.

46495	Kellogg Parsons J (2007). Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. <i>J Urol</i> , 178: 395-401.
119366	Khan S, Wolin KY, Pakpahan R, et al (2021). Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. <i>BMC Urol</i> , 21(1): 47.
119368	Kim DG, Kim DW, Park JK (2011). Does bicycle riding impact the development of lower urinary tract symptoms and sexual dysfunction in men? <i>Korean J Urol</i> , 52(5): 350-4.
119369	Kim KS, Jo JK, Lee JA, et al (2019). Do lifestyle factors affect lower urinary tract symptoms? Results from the Korean Community Health Survey. <i>Int Neurourol J</i> , 23(2): 125-35.
77104	Kirby R, McConnell JD, Fitzpatrick JM, et al (2004). Alcohol consumption and liver cirrhosis. <i>Textbook of Benign Prostatic Hyperplasia</i> , 2nd Edition, Section II, Chapter 11: 170. Taylor & Francis, London.
46861	Klein BE Klein R, Lee KE, et al (1999). Correlates of urinary symptom scores in men. <i>Am J Public Health</i> , 89(11): 1745-8.
11201	Kliwer EV (1996). Benign prostatic hyperplasia morbidity and mortality among immigrants in Australia and Canada. <i>Prostate</i> , 28(4): 211-8.
13906	Koskimaki J, Hakama M, Huhtala H, et al (1998). Association of smoking with lower urinary tract symptoms. <i>J Urol</i> , 159(5): 1580-2.
45077	Koskimaki J, Hakama M, Huhtala H, et al (2000). Association of dietary elements and lower urinary tract symptoms. <i>Scand J Urol Nephrol</i> , 34(1): 46-50.
119372	Kramer JJ, Gu L, Moreira D, et al (2022). Statin use and lower urinary tract symptoms incidence and progression in reduction by dutasteride of prostate cancer events (REDUCE) trial. <i>J Urol</i> , 207(2): 417-23.
45163	Krieger JN (2004). Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. <i>Minerva Urol Nefrol</i> , 56: 99-107.
76155	Kristal A, Arnold K, Schenk J, et al (2008). Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>Am J Epidemiol</i> , 167(8): 925-34.
44920	Kristal AR, Arnold KB, Schenk JM, et al (2007). Race/ethnicity, obesity, health related behaviours and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>J Urol</i> , 177(4): 1395-400.
76999	Kumar R, Verma V, Sarswat A, et al (2012). Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms- action of two new agents. <i>Invest New Drugs</i> , 30(2): 582-93.
77000	Kumar S, Yadav RN, Gupta P, et al (2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study. <i>Eur J Endocrinol</i> , 172(2): 97-106.
46870	Kumar V, Abbas AK, Fausto N (2004). Benign enlargement: Nodular hyperplasia (benign prostatic hyperplasia). <i>Robbins and Cotran Pathologic Basis of Disease</i> , 7th Edition, Unit II: 1048-50. Elsevier Saunders.
76178	Kumar V, Banerjee B, Datta S, et al (2014). Association of CYP1A1, CYP1B1 and CYP17 gene polymorphisms and organochlorine pesticides with benign prostate hyperplasia. <i>Chemosphere</i> , 108: 40-5.
15393	Kupeli B, Soygur T, Aydos K, et al (1997). The role of cigarette smoking in prostatic enlargement. <i>Br J Urol</i> , 80(2): 201-4.
77001	Kupelian V, Araujo AB, Wittert GA, et al (2015). Association of moderate to severe lower urinary tract symptoms with incident type 2 diabetes and heart disease. <i>J Urol</i> , 193(2): 581-6.



119375	La Vignera S, Condorelli RA, Russo GI, et al (2016). Endocrine control of benign prostatic hyperplasia. <i>Andrology</i> , 4(3): 404-11.
28952	Lacey JV Jr, Deng J, Dosemeci M, et al (2001). Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. <i>Int J Epidemiol</i> , 30(2): 341-9.
45073	Lagiou P, Wu J, Trichopoulou A, et al (1999). Diet and benign prostatic hyperplasia: a study in Greece. <i>Urology</i> , 54(2): 284-90.
11198	Lee C, Koslowski JM, Grayhack JT (1995). Etiology of benign prostatic hyperplasia. <i>Urol Clin North Am</i> , 22(2): 237-46.
11202	Lee C, Koslowski JM, Grayhack JT (1997). Intrinsic and extrinsic factors controlling benign prostatic growth. <i>Prostate</i> , 31(2): 131-8.
11205	Lee E, Park MS, Shin C, et al (1997). A high-risk group for prostatism: a population-based epidemiological study in Korea. <i>Br J Urol</i> , 79(5): 736-41.
46867	Lee S, Min HG, Choi SH, et al (2006). Central obesity as a risk factor for prostatic hyperplasia. <i>Obesity</i> , 14(1): 172-9.
14596	Lees RE, Steele R, Wardle D (1985). Arsenic, syphilis and cancer of the prostate. <i>J Epidemiol Comm Health</i> , 39(3): 227-30.
46914	Lekili M, Muezzinoglu T, Uyanik BS, et al (2006). Serum lipid levels in benign prostatic hyperplasia. <i>World J Urol</i> , 24: 210-3.
11204	Lennard MS (1989). Metoprolol-induced hepatitis: is the rate of oxidation related to drug-induced hepatotoxicity? <i>Hepatology</i> , 9(1): 163-4.
15400	Levine AC, Kirschenbaum A, Gabilove JL (1997). The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. <i>Mt Sinai J Med</i> , 64(1): 20-5.
76177	Lewis-Mikhael A, Olmedo-Requena R, Martinez-Ruiz V, et al (2015). Organochlorine pesticides and prostate cancer, is there an association? A meta-analysis of epidemiological evidence. <i>Cancer Causes Control</i> , 26(10): 1375-92.
119378	Lin TY, Chen IH, Weng HY, et al (2024). Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study. <i>World J Urol</i> , 42(1): 126.
119376	Liu AQ, Chiu PK, Yee SC, et al (2023). SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration. <i>J Intern Med</i> , 294(6): 775-83.
104214	Liu ZM, Wong CK, Chan D, et al (2016). Fruit and vegetable intake in relation to lower urinary tract symptoms and erectile dysfunction among southern Chinese elderly men: A 4-year prospective study of Mr OS Hong Kong. <i>Medicine (Baltimore)</i> , 95(4): e2557.
77002	Ma Y, Zhang WL (2010). Benign prostate hyperplasia with chronic prostatitis: an update. <i>Zhonghua Nan Ke Xue</i> , 16(7): 646-50. [Abstract]
119379	Man KM, Chen KB, Chen HY, et al (2018). Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study. <i>Medicine (Baltimore)</i> , 97(39): e12459.
46868	Marcelli M, Cunningham GR (1999). Hormonal signaling in prostatic hyperplasia and neoplasia. <i>J Clin Endocrinol Metab</i> , 84(10): 3463-8.
119381	Marshall LM, Holton KF, Parsons JK, et al (2014). Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men. <i>Prostate Cancer Prostatic Dis</i> , 17(3): 265-72.
119382	Maserejian NN, Kupelian V, Miyasato G, et al (2012). Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. <i>J Urol</i> , 188(2): 490-5.
45070	Matzkin H, Cytron S, Simon D (1996). Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? <i>Prostate</i> , 29(1): 42-5.

11189	Matzkin H, Soloway MS (1993). Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer. <i>Prostate</i> , 22(4): 277-90.
46856	McGraw-Hill's Access Medicine (2007). Hyperplastic and malignant diseases of the prostate: Introduction. <i>Harrison's Internal Medicine</i> , Chapter 81. McGraw Hill.
45029	McVary KT (2005). Erectile dysfunction and lower urinary tract symptoms secondary to BPH. <i>Eur Urol</i> , 47(6): 838-45.
119384	McVary KT (2023). Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia. Retrieved 23th February 2024, from <a href="https://www.uptodate.com/contents/clinical-manifestations-and-diagnostic-evaluation-of-benign-prostatic-hyperplasia">https://www.uptodate.com/contents/clinical-manifestations-and-diagnostic-evaluation-of-benign-prostatic-hyperplasia</a>
119385	McVary KT (2023). Epidemiology and pathophysiology of benign prostatic hyperplasia. Retrieved 23th February 2024, from <a href="https://www.uptodate.com/contents/epidemiology-and-pathophysiology-of-benign-prostatic-hyperplasia">https://www.uptodate.com/contents/epidemiology-and-pathophysiology-of-benign-prostatic-hyperplasia</a>
119387	McVary KT (2023). Patient education: Benign prostatic hyperplasia (BPH) (beyond the basics). Retrieved 24th February 2024, from <a href="https://www.uptodate.com/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics">https://www.uptodate.com/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics</a>
76525	McVary KT, Roehrborn CG, Avins AL, et al (2011). Update on AUA guideline on the management of benign prostatic hyperplasia. <i>J Urol</i> , 185(5): 1793-803.
77003	Mehta V, Vezina CM (2011). Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia. <i>Differentiation</i> , 82(4-5): 211-9.
45075	Meigs JB, Mohr B, Barry MJ, et al (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. <i>J Clin Epidemiol</i> , 54(9): 935-44.
45162	Michel M, Heemann U, Schumacher H, et al (2004). Association of hypertension with symptoms of benign prostatic hyperplasia. <i>J Urol</i> , 172(4 Pt 1): 1390-3.
45069	Michel MC, Mehlburger L, Schumacher H, et al (2000). Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>J Urol</i> , 163(6): 1725-9.
45147	Mohanty NK, Jolly BB (1996). Prevalence of bacterial prostatitis in benign prostatic hyperplasia. <i>Indian J Pathol Microbiol</i> , 39(2): 111-4.
119390	Mondul AM, Giovannucci E, Platz EA (2020). A prospective study of physical activity, sedentary behavior, and incidence and progression of lower urinary tract symptoms. <i>J Gen Intern Med</i> , 35(8): 2281-8.
11194	Montie JE, Pienta KJ (1994). Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. <i>Urology</i> , 43(6): 892-9.
74375	Moon DG, Lee KC, Kim YW, et al (2004). Effect of TCDD on corpus cavernosum histology and smooth muscle physiology. <i>Int J Impot Res</i> , 16(3): 224-30.
11195	Moon TD, Brannan W, Stone NN, et al (1994). Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. <i>J Urol</i> , 152(5 Pt 1): 1498-500.
45205	Morales A (2004). Testosterone treatment for the aging man: the controversy. <i>Curr Urol Rep</i> , 5(6): 472-7.
76202	Moreira D, Nickel J, Gerber L, et al (2015). Smoking is associated with acute and chronic prostatic inflammation: results from the REDUCE study. <i>Cancer Prev Res (Phila)</i> , 8(4): 312-7.
45200	Morrison AS (1978). Prostatic hypertrophy in greater Boston. <i>J Chron Dis</i> , 31: 357-62.

7016	Morrison AS (1992). Risk factors for surgery for prostatic hypertrophy. <i>Am J Epidemiol</i> , 135(9): 974-80.
44911	Moyad MA (2003). Lifestyle changes to prevent BPH: heart healthy = prostate healthy. <i>Urol Nurs</i> , 23(6): 439-41.
119393	Nabeeh H, Ibrahim A, Taha DE, et al (2022). Impact of COVID-19 pandemic on lower urinary tract symptoms in patients with benign prostatic hyperplasia and predictors of urine retention in such patients. <i>Low Urin Tract Symptoms</i> , 14(1): 41-6.
76136	Nandeesh H (2008). Benign prostatic hyperplasia: dietary and metabolic risk factors. <i>Int Urol Nephrol</i> , 40: 649-56.
45149	Nandeesh H, Koner BC, Dorairajan LN, et al (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. <i>Clin Chim Acta</i> , 370(1-2): 89-93.
11199	Napalkov P, Maisonneuve P, Boyle P (1995). Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. <i>Urology</i> , 46: 41-6.
28736	National Research Centre for Environmental Toxicology (ENTOX) (2002). Examination of the Potential Exposure of Royal Australian Navy (RAN) Personnel to Polychlorinated Dibenzodioxins and Polychlorinated Dibenzofurans via Drinking Water, Executive Summary. Queensland Health Scientific Services (QHSS).
46871	National Research Council (2006). Health Risks from Exposure to Low Levels of Ionizing Radiation, Beir VII Phase 2. The National Academies Press, Washington D.C.
45171	Neuhouser ML, Kristal AR, Penson DF (2004). Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. <i>Urology</i> , 64(2): 201-11.
76137	Nicholson T, Moses M, Uchtmann K, et al (2015). Estrogen receptor-alpha is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. <i>J Urol</i> , 193(2): 722-9.
76208	Nicholson TM, Ricke WA (2011). Androgens and estrogens in benign prostatic hyperplasia: past, present and future. <i>Differentiation</i> , 82(4-5): 184-199.
45164	Nickel J (2006). The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. <i>Curr Opin Urol</i> , 16(1): 5-10.
45197	Nickel JC, Downey J, Young I, et al (1999). Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. <i>BJU Int</i> , 84(9): 976-81.
44914	Nickel JC, Elhilali M, Vallancien G, et al (2005). Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. <i>BJU Int</i> , 95(4): 571-4.
119396	Noh JW, Yoo KB, Kim KB, et al (2020). Association between lower urinary tract symptoms and cigarette smoking or alcohol drinking. <i>Transl Androl Urol</i> , 9(2): 312-21.
45249	Nukui M (1997). [Epidemiologic study on diet, smoking and alcohol drinking in the relationship to prostatic weight]. <i>Nihon Hinyokika Gakkai Zasshi</i> , 88(11): 950-6 [Article in Japanese].
119398	Nygaard LH, Talala K, Taari K, et al (2017). The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. <i>Prostate</i> , 77(9): 1029-35.
11184	Nygaard LH, Talala K, Taari K, et al (2023). Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. <i>Prostate</i> , 83(3): 246-58.
45391	Ochiai A, Fritsche HA, Babaian RJ (2005). Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. <i>Urology</i> , 66: 819-23.

15396	Ohno Y, Yoshida O, Oishi K, et al (1988). Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. <i>Cancer Res</i> , 48(5): 1331-6.
31615	Oishi K, Okada K, Yoshida O, et al (1990). A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors. <i>Prostate</i> , 17(4): 269-79.
30703	Oishi K, Okada K, Yoshida O, et al (1998). A case-control study of prostatic cancer with reference to dietary habits. <i>Prostate</i> , 12(2): 179-90.
15395	O'Leary MP (1995). Epidemiology of benign prostatic hyperplasia. <i>Br J Urol</i> , 76(Suppl 1): 1-3.
45914	Overland GB, Vatten L, Rhodes T, et al (2001). Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. <i>Eur Urol</i> , 39: 36-41.
70194	Ozasa K, Shimizu Y, Suyama A, et al (2012). Studies of the mortality of atomic bomb survivors, Report 14, 1950-2003: an overview of cancer and noncancer diseases. <i>Radiat Res</i> , 177(3): 229-43; Erratum: 179(4): e40-1.
11489	Pagano F (1991). Is benign prostatic hyperplasia a premalignant condition? <i>Prospectives: Contemporary Issues in Managing Prostatic Disease</i> , 1(7): 1-3, 6-8.
77004	Paolone DR (2010). Benign prostatic hyperplasia. <i>Clin Geriatr Med</i> , 26(2): 223-39.
119400	Park HJ, Park CH, Chang Y, et al (2018). Sitting time, physical activity and the risk of lower urinary tract symptoms: a cohort study. <i>BJU Int</i> , 122(2): 293-9.
119402	Park JS, Koo KC, Kim HK, et al (2019). Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. <i>Medicine (Baltimore)</i> , 98(42): e17635.
76139	Parnham A, Haq A (2013). Benign prostatic hyperplasia. <i>J Clin Urol</i> , 6(1): 24-31.
76135	Parsons J (2011). Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>Curr Opin Urol</i> , 21(1): 1-4.
76144	Parsons J, Kashefi C (2008). Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>Eur Urol</i> , 53(6): 1228-35.
76203	Parsons J, Messer K, White M, et al (2011). Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the osteoporotic fractures in men study. <i>Eur Urol</i> , 60(6): 1173-80.
76152	Parsons JK (2010). Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. <i>Curr Bladder Dysfunct Rep</i> , 5: 212-8.
44916	Parsons JK, Carter HB, Partin AW, et al (2006). Metabolic factors associated with benign prostatic hyperplasia. <i>J Clin Endocrinol Metab</i> , 91: 2562-8.
76141	Parsons JK, Im R (2009). Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. <i>J Urol</i> , 182(4): 1463-8.
76133	Parsons JK, Sarma AV, McVary K, et al (2013). Obesity and benign prostatic hyperplasia: clinical connections emerging etiological paradigms and future directions. <i>J Urol</i> , 189(1 Suppl): S102-6.
45203	Partin AW (2000). Etiology of benign prostatic hyperplasia. Lepor H, (ed). <i>Prostatic diseases</i> . Philadelphia, PA: Saunders, : 95-105.
76284	Partin AW, Oesterling JE, Epstein JI (1991). Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. <i>J Urol</i> , 145(2): 405-9. [Abstract]
45355	Pasquali R, Casimirri F, Cantobelli S, et al (1991). Effect of obesity and body fat distribution on sex hormones and insulin in men. <i>Metabolism</i> , 40(1): 101-4.

76134	Patel N, Parsons J (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. <i>Indian J Urol</i> , 30(2): 170-6.
119405	Peng YH, Huang CW, Liao WC, et al (2017). Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study. <i>BMJ Open</i> , 7(6): e015581.
46857	Petersen LA (1998). Recent advances: general medicine. <i>BMJ</i> , 317(7161): 792-5.
15394	Platz EA, Kawachi I, Rimm EB, et al (1998). Physical activity and benign prostatic hyperplasia. <i>Arch Intern Med</i> , 158: 2349-56.
46859	Platz EA, Rimm EB, Kawachi I, et al (1999). Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. <i>Am J Epidemiol</i> , 149(2): 106-15.
11191	Porta M, Fernandez E, Alonso J, et al (1994). Re: risk factors for benign prostatic hypertrophy. <i>Am J Epidemiol</i> , 139(1): 114-5.
44922	Potter SR, Partin AW (1999). Prostatitis syndromes and benign prostatic hyperplasia. <i>Semin Roentgenol</i> , 34(4): 256-68.
45248	Prezioso D, Catuogno C, Galassi P, et al (2001). Life-style in patients with LUTS suggestive of BPH. <i>Eur Urol</i> , 40(Suppl 1): 9-12.
119407	Privitera S, Russo GI, La Vignera S, et al (2018). Benign prostatic hyperplasia and intraprostatic inflammation are associated with liver inflammation: it's time for prevention. <i>Andrology</i> , 6(5): 737-41.
76179	Ragin C, Davis-Reyes B, Tadesse H, et al (2013). Farming, reported pesticide use, and prostate cancer. <i>Am J Mens Health</i> , 7(2): 102-9.
76175	Raheem O, Parsons J (2014). Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. <i>Curr Opin Urol</i> , 24(1): 10-4.
45022	Ranjan P, Dalela D, Sankhwar SN (2006). Diet and benign prostatic hyperplasia: implications for prevention. <i>Urology</i> , 68(3): 470-6.
119403	Rastrelli G, Cipriani S, Lotti F, et al (2022). Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. <i>J Endocrinol Invest</i> , 45(7): 1413-25.
119409	Rastrelli G, Vignozzi L, Corona G, et al (2019). Testosterone and benign prostatic hyperplasia. <i>Sex Med Rev</i> , 7(2): 259-71.
32521	Rhoden EL, Morgentaler A (2004). Risks of testosterone-replacement therapy and recommendations for monitoring. <i>N Engl J Med</i> , 350(5): 482-92.
76176	Robert G (2010). Inflammation and benign prostatic hyperplasia: cause or consequence? <i>Prog Urol</i> , 20(6): 402-7. [Abstract]
46860	Roberts Ro, Jacobsen SJ (1999). [Comment] Re: "alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia". <i>Am J Epidemiol</i> , 150(3): 321.
11193	Roberts RO, Jacobsen SJ, Rhodes T, Guess HA, et al (1994). Cigarette smoking and prostatism: a biphasic association? <i>Urology</i> , 43(6): 797-9.
15399	Roberts RO, Tsukamoto T, Kumamoto Y, et al (1997). Association between cigarette smoking and prostatism in a Japanese community. <i>Prostate</i> , 30(3): 154-9.
15548	Roehrborn CG (1994). Some socio-economic issues surrounding prostatectomy: the US experience. <i>Prog Clin Biol Res</i> , 386: 419-25.
76142	Roehrborn CG (2008). Pathology of benign prostatic hyperplasia. <i>Int J Impot Res</i> , 20(Suppl 3): S11-8.

77105	Roehrborn CG, Cassab A, Glina S, et al (2015). Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. <i>Int J Urol</i> , 22(6): 582-7.
47020	Roehrborn CG, Marberger M, Wolford ET, et al (2006). Relationships between alcohol use and measures of LUTS/BPH severity: baseline data from dutasteride studies involving a total of 18,914 subjects. Retrieved 26 February 2008, from <a href="http://www.urotoday.com/index2.php?option=com_content&amp;task=view&amp;id=20242&amp;I">http://www.urotoday.com/index2.php?option=com_content&amp;task=view&amp;id=20242&amp;I</a>
45392	Rohrmann S, Crespo CJ, Weber JR, et al (2005). Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health and Nutrition Examination Survey. <i>BJU</i> , 96: 77-82.
45393	Rohrmann S, Fallin MD, Page WF, et al (2006). Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. <i>Epidemiology</i> , 17: 419-27.
44919	Rohrmann S, Giovannucci E, Willett WC, et al (2007). Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. <i>Am J Clin Nutr</i> , 85: 523-9.
119411	Rohrmann S, Katzke VA, Kaaks R (2018). Lifestyle and progression of lower urinary tract symptoms in German men-results from the EPIC-Heidelberg cohort. <i>Urology</i> , 120: 192-6.
45195	Rohrmann S, Platz EA, Smit E, et al (2004). [Comment] Re: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. <i>J Urol</i> , 172(2): 779.
45358	Rohrmann S, Smit E, Giovannucci E, et al (2004). Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. <i>Am J Epidemiol</i> , 159(4): 390-7.
45390	Rohrmann S, Smit E, Giovannucci E, et al (2005). Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). <i>Int J Obes (Lond)</i> , 29(3): 310-6.
7210	Ross RK, Bernstein L, Paganini-Hill A, et al (1990). Effects of cigarette smoking on 'hormone-related' diseases in a Southern California retirement community. <i>Smoking and Hormone-Related Disorders</i> , Oxford University Press, Oxford.
119413	Russo GI, Broggi G, Cocci A, et al (2021). Relationship between dietary patterns with benign prostatic hyperplasia and erectile dysfunction: a collaborative review. <i>Nutrients</i> , 13(11): 4148.
119414	Russo GI, Cimino S, Castelli T, et al (2016). Benign prostatic hyperplasia, metabolic syndrome and non-alcoholic fatty liver disease: is metaflammation the link? <i>Prostate</i> , 76(16): 1528-35.
76358	Saad F, Haider A, Yassin A, et al (2014). 156 hypogonadal men with obesity and type 2 diabetes achieve weight loss and improved glycaemic control upon treatment with testosterone undecanoate up to 6 years: a subgroup analysis from two observational registry studies. <i>J Mens Health</i> , 11(1): A4-5. [Abstract]
45386	Sandfeldt L, Hahn RG (2003). Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. <i>BJU Int</i> , 92(1): 64-8.
11192	Santti R, Newbold RR, Makela S, et al (1994). Developmental estrogenization and prostatic neoplasia. <i>Prostate</i> , 24(2): 67-78.

45357	Sarma AV, Jaffee CA, Schottenfeld D, et al (2002). Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. <i>Urology</i> , 59(3): 362-7.
76210	Sarma AV, Parsons JK, McVary K, et al (2009). Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know? <i>J Urol</i> , 182(6 Suppl): S32-7.
45705	Schechter A, Birnbaum L, Ryan JJ, et al (2006). Dioxins: an overview. <i>Environ Res</i> , 101(3): 419-28.
119417	Schenk JM, Calip GS, Tangen CM, et al (2012). Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>Am J Epidemiol</i> , 176(2): 156-63.
45170	Schultheiss D, Machtens S, Jonas U (2004). Testosterone therapy in the ageing male: what about the prostate? <i>Andrologia</i> , 36: 355-65.
11259	Scolnik MD, Servadio C, Abramovici A (1994). Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. <i>J Androl</i> , 15(4): 287-97.
76204	Sea J, Poon KS, McVary KT (2009). Review of exercise and the risk of benign prostatic hyperplasia. <i>Phys Sportsmed</i> , 37(4): 75-83.
46915	Seim A, Hoyo C, Ostbye T, et al (2005). The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT Study. <i>BJU Int</i> , 96(1): 88-92.
7018	Seitter WR, Barrett-Connor E (1992). Cigarette smoking, obesity and benign prostatic hypertrophy: a prospective population-based study. <i>Am J Epidemiol</i> , 135(5): 500-3.
11188	Sevim M, Alkis O, Kartal İG, et al (2023). Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study. <i>Prostate</i> , 83(1): 82-6.
45024	Shakya G, Malla S, Shakya KN (2003). Salient and co-morbid features in benign prostatic hyperplasia: a histopathological study of the prostate. <i>Kathmandu Univ Med J (KUMJ)</i> , 1(2): 104-9.
119420	Shigehara K, Namiki M (2011). Late-onset hypogonadism syndrome and lower urinary tract symptoms. <i>Korean J Urol</i> , 52(10): 657-63.
119423	Shih HJ, Huang CJ, Lin JA, et al (2018). Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. <i>Prostate</i> , 78(2): 113-20.
29371	Siddiqui MK, Srivastava S, Mehrotra PK (2002). Environmental exposure to lead as a risk for prostate cancer. <i>Biomed Environ Sci</i> , 15(4): 298-305.
45199	Sidney S, Quesenberry C Jr, Sadler MC, et al (1991). Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. <i>Urology</i> , 38(1 Suppl): 13-9.
45074	Signorello LB, Tzonou A, Lagiou P, et al (1999). The epidemiology of benign prostatic hyperplasia: a study in Greece. <i>BJU Int</i> , 84(3): 286-91.
45071	Simpson RJ, Fisher W, Lee AJ, et al (1996). Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. <i>Br J Urol</i> , 77(2): 186-91.
45167	Skolarikos A, Thorpe AC, Neal DE (2004). Lower urinary tract symptoms and benign prostatic hyperplasia. <i>Minerva Urol Nefrol</i> , 56(2): 109-22.
76191	Smith D, Weber M, Soga K, et al (2014). Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,436 middle-aged and older Australian men: population-based study. <i>PLoS One</i> , 9(10): e109278.
119427	Snyder PJ (2022). The benefits and risks of testosterone treatment in older hypogonadal men. <i>Endocrinol Metab Clin North Am</i> , 51(1): 149-56.

11405	Soygur T, Kupeli B, Aydos K, et al (1996). Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. <i>Int Urol Nephrol</i> , 28(1): 55-9.
119428	St Sauver JL, Jacobson DJ, McGree ME, et al (2006). Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. <i>Am J Epidemiol</i> , 164(8): 760-8.
119430	St Sauver JL, Jacobson DJ, McGree ME, et al (2008). Longitudinal association between prostatitis and development of benign prostatic hyperplasia. <i>Urology</i> , 71(3): 475-9.
119432	St Sauver JL, Sarma AV, Hollingsworth JM, et al (2011). Associations between modest weight changes and onset and progression of lower urinary tract symptoms in two population-based cohorts. <i>Urology</i> , 78(2): 437-41.
76279	Stamatiou K, Copanitsanou P (2012). Is there any association between obesity and benign prostatic hyperplasia? <i>Int J Urol Nurs</i> , 6(1): 11-6.
29250	Steele R, Lees RE, Kraus AS, et al (1971). Sexual factors in the epidemiology of cancer of the prostate. <i>J Chron Dis</i> , 24(1): 29-37.
46865	Sutcliffe S, Giovannucci E, De Marzo AM, et al (2005). Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. <i>Am J Epidemiol</i> , 162(9): 898-906.
119433	Sutcliffe S, Grubb lii RL, Platz EA, et al (2012). Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>BJU Int</i> , 110(7): 1050-9.
46864	Suzuki S, Platz EA, Kawachi I, et al (2002). Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. <i>Am J Clin Nutr</i> , 75(4): 689-97.
45166	Tan RS, Salazar (2004). Risks of testosterone replacement therapy in aging men. <i>Expert Opin. Drug Saf</i> , 3(6): 599-606.
45025	Thorpe A, Neal D (2003). Benign prostatic hyperplasia. <i>Lancet</i> , 361: 1359-67, 1359-67. Erratum: 362,496.
45079	Toth M, Patton DL, Campbell LA, et al (2000). Detection of chlamydial antigenic material in ovarian, prostatic, ectopic pregnancy and semen samples of culture-negative subjects. <i>Am J Reprod Immunol</i> , 43(4): 218-22.
76209	Tseng C (2013). Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the national health insurance in Taiwan. <i>BMC Cancer</i> , 13: 7.
119435	Tsunemori H, Sugimoto M (2021). Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. <i>Int J Urol</i> , 28(11): 1086-92.
46866	Ullrich PM, Lutgendorf SK, Leserman J, et al (2005). Stress, hostility, and disease parameters of benign prostatic hyperplasia. <i>Psychosom Med</i> , 67(3): 476-82.
46734	Usai E, Scarpa RM, De Lisa A, et al (1995). Benign prostatic hyperplasia: associated pathology. <i>J Urol (Paris)</i> , 101(1): 53-54.
76289	Vikram A, Jena G, Ramarao P (2010). Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostatic hyperplasia. <i>Prostate</i> , 70(1): 79-89.
76288	Vikram A, Jena G, Ramarao P (2010). Insulin-resistance and benign prostatic hyperplasia: the connection. <i>Eur J Pharmacol</i> , 641(2-3): 75-81.
15550	Villers A (1994). Anatomy of the prostate: insight into benign prostatic hyperplasia anatomy and pathogenesis. <i>Prog Clin Biol Res</i> , 386: 21-30.



76287	Wallner L, Hollingsworth J, Dunn R, et al (2013). Hyperglycemia, hyperinsulinemia, insulin resistance and the risk of BPH/LUTS severity and progression over time in community dwelling black men: the flint men's health study. <i>Urology</i> , 84(4): 881-6.
11203	Walsh PC (1988). The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia. <i>J Urol</i> , 139(4): 826.
76281	Wang S, Mao Q, Lin Y, et al (2012). Body mass index and risk of BPH: a meta-analysis. <i>Prostate Cancer Prostatic Dis</i> , 15(3): 265-72.
76138	Wang W, Guo Y, Zhang D, et al (2015). The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. <i>Sci Rep</i> , 5: 13546.
11197	Wemyss-Holden SA, Hamdy FC, Hastie KJ (1994). Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction - is there a relationship? <i>Br J Urol</i> , 74(4): 476-8.
15401	Wideroff L, Schottenfeld D, Carey TE, et al (1996). Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. <i>Prostate</i> , 28: 117-23.
76143	Wolin K, Grubb R, Pakpahan R, et al (2015). Physical activity and benign prostatic hyperplasia - related outcomes and nocturia. <i>Med Sci Sports Exerc</i> , 47(3): 581-92.
45220	Wong SY, Hong A, Leung J, et al (2006). Lower urinary tract symptoms and depressive symptoms in elderly men. <i>J Affect Disord</i> , 96(1-2): 83-8.
119473	Wu Y, Xu D, Shen HB, et al (2020). The association between body mass index and testosterone deficiency in aging Chinese men with benign prostatic hyperplasia: results from a cross-sectional study. <i>Aging Male</i> , 23(5): 841-6.
45169	Xie LP, Bai Y, Zhang XZ, et al (2007). Obesity and benign prostatic enlargement: a large observational study in China. <i>Urology</i> , 69(4): 680-4.
119474	Xin C, Fan H, Xie J, et al (2022). Impact of diabetes mellitus on lower urinary tract symptoms in benign prostatic hyperplasia patients: a meta-analysis. <i>Front Endocrinol (Lausanne)</i> , 12: 741748.
119475	Xu H, Fu S, Chen Y, et al (2016). Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies. <i>Medicine (Baltimore)</i> , 95(32): e4565.
119476	Yang X, Zhang Q, Jiang G, et al (2019). The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: a meta-analysis. <i>Medicine (Baltimore)</i> , 98(18): e15502.
119477	Zhang X, Xiao L, Zhang L, et al (2022). Associated factors for prostate enlargement in Chinese adult men aged <40 receiving checkups. <i>Int J Clin Pract</i> , 2022: 4792451.
45359	Zhuang TN, Ly LP, Cumming RG, et al (2005). Growth and development during early manhood as determinants of prostate size in later life. <i>J Clin Endocrinol Metab</i> , 90(11): 6055-63.
45204	Zucchetto A, Tavani A, Dal Maso L, et al (2005). History of weight and obesity through life and risk of benign prostatic hyperplasia. <i>Int J Obes (Lond)</i> , 29(7): 798-803.